AstraZeneca requests emergency use authorization for COVID-19 prophylaxis treatment
AstraZeneca today said it has requested an emergency use authorization from the Food and Drug Administration for its long-acting antibody combination for the prevention of symptomatic COVID-19. According to AstraZeneca, phase 3 trial data showed that AZD7442, when administered pre-exposure as prophylaxis, reduced the risk of developing symptomatic COVID-19 by 77%.
Related News Articles
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…